Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by PoorOpinionon Mar 19, 2018 11:20am

122 Views

Post# 27739466

RE:RE:The suspense is killing me

Jefferam1 wrote:
Anyone know, does topstone need to coordinate anything with the governing body?
Or is that the responsibility of Antibe?
I'm just wondering if potentialy that is the delay.
If they are waiting on whatever the Canadian equilivant is for the FDA, I imagine they can't be very fast.
Although If I had to guess, I'd be guessing it's Antibe responsibility to work with them?

That is not an issue. No role for Health Canada in this news release.

Bullboard Posts

From now on, dynaCERT instead of Bitcoin or NVIDIA?